Amylyx Pharmaceuticals, Inc.

AMLX Healthcare Drug Manufacturers Specialty & Generic

Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

26.34 1.31 −4.74%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−9.2×
Dividend yield
—
F-score
3/9
Altman Z
−2.95
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
12.12 17.85 14.27 13.70
Net Debt/EBITDA
5.35 6.32 8.44 9.26
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.28) (0.37) (0.30) (0.33)
Book value per Share
2.15 2.47 3.23 3.56
Free Cash Flow
(31.45) (40.88) (27.99) (30.39)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates